rogaratinib (BAY 1163877) / Bayer 
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rogaratinib (BAY 1163877) / Bayer
FORT-2, NCT03473756 / 2017-001483-38: Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

Completed
1
37
Europe, Japan, US, RoW
Rogaratinib (BAY1163877), Atezolizumab
Bayer
Urothelial Carcinoma
07/21
07/24
ROGABREAST, NCT04483505: Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

Completed
1
9
Europe
Combination, Rogaratinib + palbociclib + fulvestrant
Fundacion CRIS de Investigación para Vencer el Cáncer, Bayer, Pfizer, Apices Soluciones S.L.
Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
04/23
04/23

Download Options